for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   United European Gastroenterology Journal
  [2 followers]  Follow
   Hybrid Journal Hybrid journal (It can contain Open Access articles)
   ISSN (Print) 2050-6406 - ISSN (Online) 2050-6414
   Published by Sage Publications Homepage  [827 journals]
  • The genetic epidemiology of diverticulosis and diverticular disease:
           Emerging evidence
    • Authors: Reichert, M. C; Lammert, F.
      Pages: 409 - 418
      Abstract: Diverticular disease (DD) is one of the most prevalent gastrointestinal disorders. The pathogenesis of diverticulosis and DD is controversially discussed. Current studies call the traditional concept of a fibre-deficient diet causing the development of diverticula into question. Data from two recent twin studies have provided conclusive evidence for a strong genetic component to diverticulosis. Although genomewide association studies have provided new insights into the polygenic architecture of human diseases, genomic research in diverticulosis and DD has just been started. This is an astonishing fact given the high morbidity and mortality of the disease, as well as the substantial economic burden on health care systems. For this review, we provide an update of the molecular pathobiology and summarise recent evidence supporting the hypothesis that distinct, yet unidentified genetic variants contribute to the development of diverticulosis and DD.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615576676
      Issue No: Vol. 3, No. 5 (2015)
  • Biologics in inflammatory bowel disease: what are the data'
    • Authors: Cote-Daigneault, J; Bouin, M, Lahaie, R, Colombel, J.-F, Poitras, P.
      Pages: 419 - 428
      Abstract: Background Over the last decade, biologics have gained an important place for the treatment of moderate to severe inflammatory bowel disease (IBD), and many randomized control trials have evaluated their efficacy. Aim The goal of this review is to analyze the results of these trials and to highlight the evidence and indications emerging from these studies for their implementation in the management of IBD patients. Methods A PubMed search was realized to screen high-quality clinical trials studying biologic agents currently available in clinics for the treatment of IBD. Words used were: "infliximab," "adalimumab," "certolizumab," "golimumab," "natalizumab," "vedolizumab," "ustekinumab," "azathioprine," "methotrexate," "Crohn's disease," and "ulcerative colitis." Results In Crohn's disease, studies supporting induction and maintenance therapies were documented for infliximab, adalimumab, certolizumab, natalizumab, vedolizumab, and ustekinumab. Infliximab, adalimumab, and certolizumab have evidences for fistulizing Crohn's disease and only infliximab and adalimumab have evidences for mucosal healing. In ulcerative colitis, studies supporting induction, maintenance, and mucosal healing were found with infliximab, adalimumab, golimumab, and vedolizumab. Only infliximab was associated with evidences for combination therapy with thiopurine and acute severe colitis in ulcerative colitis. Conclusion Management with biologics in IBD patients is well validated by high-quality clinical trials.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615590302
      Issue No: Vol. 3, No. 5 (2015)
  • Diagnostic methods for H. pylori infection: Choices, opportunities and
    • Authors: Malfertheiner; P.
      Pages: 429 - 431
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615600968
      Issue No: Vol. 3, No. 5 (2015)
  • A combined antral and corpus rapid urease testing protocol can increase
           diagnostic accuracy despite a low prevalence of Helicobacter pylori
           infection in patients undergoing routine gastroscopy
    • Authors: Parihar, V; Holleran, G, Hall, B, Brennan, D, Crotty, P, McNamara, D.
      Pages: 432 - 436
      Abstract: Background The effects of an increased risk of sampling error and the lower prevalence of Helicobacter pylori infection on the diagnostic accuracy of standard invasive tests needs to be considered. Despite evidence of enhanced yield with additional biopsies, combined Rapid Urease Tests (RUTs) have not been widely adopted. We aimed to compare the diagnostic efficacy of a combined antral and corpus rapid urease test (RUT) to a single antral RUT in a low prevalence cohort. Methods Between August 2013 and April 2014 adult patients undergoing a scheduled gastroscopy were prospectively recruited. At endoscopy biopsies were taken and processed for single and combined RUTs, histology and culture using standard techniques. Infection was defined by positive culture or detection of Helicobacter like organisms on either antral or corpus samples. Results In all 123 patients were recruited. H. pylori prevalence was low at 36%, n = 44. There was a significant difference in positivity between single and combined RUTs, 20% (n = 25) versus 30% (n = 37), p = 0.0094, (95% CI 0.15–0.04). The number needed to treat (NNT) for an additional diagnosis of infection using a combined versus a single RUT is 4 (95% CI 2.2–11). The only factor associated with a reduction in RUT yield was regular proton pump inhibitor (PPI) use. Overall the sensitivity, specificity, positive and negative predictive value for any RUT test was 84%, 100%, 100% and 92% respectively. Conclusion Our data suggests taking routine antral and corpus biopsies in conjunction with a combined RUT appears to optimizing H. pylori detection and overcome sampling error in a low prevalence population.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615573374
      Issue No: Vol. 3, No. 5 (2015)
  • Occult H. pylori infection partially explains 'false-positive' results of
           13C-urea breath test
    • Authors: Ramirez-Lazaro, M. J; Lario, S, Calvet, X, Sanchez-Delgado, J, Montserrat, A, Quilez, E. M, Casalots, A, Suarez, D, Campo, R, Brullet, E, Junquera, F, Sanfeliu, I, Segura, F.
      Pages: 437 - 442
      Abstract: Background In a previous study, UBiT-100 mg, (Otsuka, Spain), a commercial 13C-urea breath test omitting citric acid pre-treatment, had a high rate of false-positive results; however, it is possible that UBiT detected low-density ‘occult’ infection missed by other routine reference tests. We aimed to validate previous results in a new cohort and to rule out the possibility that false-positive UBiT were due to an ‘occult’ infection missed by reference tests. Methods Dyspeptic patients (n = 272) were prospectively enrolled and UBiT was performed, according to the manufacturer’s recommendations. Helicobacter pylori infection was determined by combining culture, histology and rapid urease test results. We calculated UBiT sensitivity, specificity, positive and negative predictive values (with 95% CI). In addition, we evaluated ‘occult’ H. pylori infection using two previously-validated polymerase chain reaction (PCR) methods for urease A (UreA) and 16 S sequences in gastric biopsies. We included 44 patients with a false-positive UBiT, and two control groups of 25 patients each, that were positive and negative for all H. pylori tests. Results UBiT showed a false-positive rate of 17%, with a specificity of 83%. All the positive controls and 12 of 44 patients (27%) with false-positive UBiT were positive for all two PCR tests; by contrast, none of our negative controls had two positive PCR tests. Conclusions UBiT suffers from a high rate of false-positive results and sub-optimal specificity, and the protocol skipping citric acid pre-treatment should be revised; however, low-density ‘occult’ H. pylori infection that was undetectable by conventional tests accounted for around 25% of the ‘false-positive’ results.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615572723
      Issue No: Vol. 3, No. 5 (2015)
  • Gender differences in symptoms in partial responders to proton pump
           inhibitors for gastro-oesophageal reflux disease
    • Authors: Vakil, N; Niklasson, A, Denison, H, Ryden, A.
      Pages: 443 - 452
      Abstract: Background Gender differences may exist in the symptom experience of patients with gastro-oesophageal reflux disease (GERD) who have a partial response to proton pump inhibitors (PPIs). Objective The purpose of this study was to analyse gender differences in partial responders to PPIs. Methods Patients with GERD who responded partially to PPIs (n = 580; NCT00703534) completed the Reflux Symptom Questionnaire 7-day recall (RESQ-7) and the Gastrointestinal Symptom Rating Scale (GSRS). Anxiety and depression were evaluated using the Hospital Anxiety and Depression Scale. Results Women had significantly higher RESQ-7 domain scores than men for Heartburn (frequency: 4.3 vs 3.9; intensity: 3.1 vs 2.8), Burping (frequency: 4.9 vs 4.4; intensity: 3.1 vs 2.8) and Hoarseness, cough and difficulty swallowing (frequency: 2.6 vs 2.2; intensity: 1.8 vs 1.5), and had higher GSRS domain discomfort scores than men for Abdominal pain (3.51 vs 3.23), Indigestion (3.80 vs 3.45) and Constipation (2.69 vs 2.17) (all p < 0.05). Anxiety and depression were significantly more prevalent in women than in men. Conclusion In this population of partial responders, women had more frequent/intense heartburn and extra-oesophageal symptoms and more discomfort from abdominal pain, indigestion and constipation than men. Comorbid anxiety and depression may contribute to the increased symptom burden in women.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640614558343
      Issue No: Vol. 3, No. 5 (2015)
  • A phase II study of TRC105 in patients with hepatocellular carcinoma who
           have progressed on sorafenib
    • Authors: Duffy, A; Ulahannan, S, Cao, L, Rahma, O, Makarova-Rusher, O, Kleiner, D, Fioravanti, S, Walker, M, Carey, S, Yu, Y, Venkatesan, A, Turkbey, B, Choyke, P, Trepel, J, Bollen, K, Steinberg, S, Figg, W, Greten, T.
      Pages: 453 - 461
      Abstract: Background Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature of many tumor types, including hepatocellular carcinoma (HCC). TRC105 is a chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth by endothelial cell growth inhibition, ADCC and apoptosis, and complements VEGF inhibitors. Objective The aim of this phase II study was to evaluate the efficacy of anti-endoglin therapy with TRC105 in patients with advanced HCC, post-sorafenib. Methods Patients with HCC and compensated liver function (Childs-Pugh A/B7), ECOG 0/1, were enrolled to a single-arm, phase II study of TRC105 15 mg/kg IV every two weeks. Patients must have progressed on or been intolerant of prior sorafenib. A Simon optimal two-stage design was employed with a 50% four-month PFS target for progression to the second stage. Correlative biomarkers evaluated included DCE-MRI as well as plasma levels of angiogenic biomarkers and soluble CD105. Results A total accrual of 27 patients was planned. However, because of lack of efficacy and in accordance with the Simon two-stage design, 11 patients were enrolled. There were no grade 3/4 treatment-related toxicities. Most frequent toxicities were headache (G2; N = 3) and epistaxis (G1; N = 4). One patient had a confirmed partial response by standard RECIST criteria and biologic response on DCE-MRI but the four-month PFS was insufficient to proceed to the second stage of the study. Conclusions: TRC105 was well tolerated in this HCC population following sorafenib. Although there was evidence of clinical activity, this did not meet prespecified criteria to proceed to the second stage. TRC105 development in HCC continues as combination therapy with sorafenib.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615583587
      Issue No: Vol. 3, No. 5 (2015)
  • Inflammatory bowel disease-specific pregnancy knowledge of
           gastroenterologists against general practitioners and obstetricians
    • Authors: Kashkooli, S. B; Andrews, J. M, Roberts, M. B, Selinger, C. P, Leong, R. W.
      Pages: 462 - 470
      Abstract: Background Patients with inflammatory bowel disease (IBD) tend to have smaller family sizes. Health care professionals (HCPs) may inadvertently provide inaccurate advice to patients resulting in voluntary childlessness or unfavourable pregnancy outcomes. Objective The study aims to objectively measure IBD-specific pregnancy-related knowledge of general practitioners (GPs) and obstetricians/gynaecologists (OB/GYNs) in comparison with gastroenterologists (GEs) using the validated Crohn’s and Colitis Pregnancy Knowledge (CCPKnow) questionnaire. Methods GPs, OB/GYNs and GEs in two Australian states completed the CCPKnow (range 0–17) and demographic questionnaires. The CCPKnow addresses issues pertaining to conception, IBD inheritance, risk of congenital abnormalities, medication use in the peri-conceptual period, pregnancy and breastfeeding, and mode of delivery. Results In total, 337 HCPs responded. GPs (n = 188/2086) and OB/GYNs (n = 94/228) had significantly lower knowledge than GEs (n = 55/165) for the composite CCPKnow (medians 11, 13 and 17, respectively, p < 0.001), and almost all domains. GEs were the only group to attain a median CCPKnow score in the top category (14–17). More than 70% of GPs and OB/GYNs expressed discomfort with initiation of IBD medications around conception/pregnancy. GPs (43.6%) and OB/GYNs (45.7%) perceived thiopurine use to be unsafe during pregnancy and to cause serious harm to the baby. Conclusions Our study demonstrates that GPs and OB/GYNs have inadequate and variable IBD-specific pregnancy-related knowledge including use of IBD medications. These results support the need for GEs’ prime role in a team-based management for IBD patients who are pregnant or planning pregnancy.
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615580893
      Issue No: Vol. 3, No. 5 (2015)
  • Efficacy and safety of naloxegol in patients with opioid-induced
           constipation and laxative-inadequate response
    • Authors: Tack, J; Lappalainen, J, Diva, U, Tummala, R, Sostek, M.
      Pages: 471 - 480
      Abstract: Background Treatment options for patients with opioid-induced constipation (OIC) and inadequate response to laxatives (LIR) are few. Objective Assess the efficacy and safety of orally administered naloxegol in patients with prospectively confirmed OIC and LIR Methods We analyzed pooled data from two identical randomized, double-blind, placebo-controlled, Phase 3 trials of naloxegol in patients with non-cancer pain, OIC and LIR in which naloxegol (12.5 mg, n = 240; 25 mg, n = 241) or placebo (n = 239) were administered daily. We assessed the response rates, time to first post-dose laxation, spontaneous bowel movements (SBMs), OIC symptoms and patient-reported outcomes over 12 weeks. Results OIC response rates for the naloxegol 25-mg (p < 0.001) and the 12.5-mg (p = 0.005) LIR dose groups were higher than placebo. Median times to first post-dose SBM were 7.6, 19.2 and 41.1 hours for the naloxegol 25 mg, naloxegol 12.5 mg and placebo groups, respectively. Other SBM measures, daily symptoms of OIC, and both the Patient Assessment of Constipation - Symptoms and Patient Assessment of Constipation-Quality of Life scores improved from baseline with naloxegol treatment. Changes from baseline in opioid dose, pain scores and opioid withdrawal scores were similar among treatment groups. Conclusions Naloxegol was efficacious, generally safe and well tolerated in the patients with OIC and LIR, while preserving opioid analgesia. identifiers: NCT01309841; NCT01323790
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615604543
      Issue No: Vol. 3, No. 5 (2015)
  • Continuous education in gastroenterology: the present and the future
    • Authors: Hammer; H. F.
      Pages: 481 - 482
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615607262
      Issue No: Vol. 3, No. 5 (2015)
  • UEG LINK Award from the National Societies to HaPanEU: Harmonising the
           diagnosis and treatment of Pancreatitis across EUrope
    • Authors: Lohr; J.-M.
      Pages: 483 - 483
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615607263
      Issue No: Vol. 3, No. 5 (2015)
  • UEG Week in Vienna 2016--advancing science, linking people
    • Authors: Simren; M.
      Pages: 484 - 484
      PubDate: 2015-09-28T07:46:32-07:00
      DOI: 10.1177/2050640615607264
      Issue No: Vol. 3, No. 5 (2015)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015